Pay in 4 interest-free payments of $25.00 Learn more
Ships within 48 hours · Estimated delivery Jul 27 - Aug 1
a pan-Janus-activated kinase inhibitor
InChi: InChI=1S/C52H65ClN12O8S/c1-65(24-8-20-55-51(69)56-22-26-72-28-30-73-29-27-71-25-21-54-45(66)14-5-4-13-44-48-43(34-74-44)62-52(70)64-48)23-7-15-46(67)59-36-18-16-35(17-19-36)49(68)60-37-9-6-10-38(31-37)61-50-58-33-41(53)47(63-50)40-32-57-42-12-3-2-11-39(40)42/h2-3
CAS Number: 694433-59-5
Specificity of polyclonal antibodies raised against a novel 24
Deleobuvir ylamino-Val-Cit-OH a pan-Janus-activated kinase inhibitorDeleobuvir, also known as BI207127, a non nucleoside hepatitis C virus NS5B polymerase inhibitor for the treatment of hepatitis C. Deleobuvir was tested in combination regimens with pegylated interferon and ribavirin, and in interferon free regimens with other direct acting antiviral agents including faldaprevir. Deleobuvir showed that a triple combination of deleobuvir, faldaprevir, and ribavirin performed well in HCV genotype 1b patients. Efficacy
US$ 195.00
US$ 114.51